Clinical Trials
26 trialsIs Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Tianjin Medical University Second Hospital
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
HIVEC
AC.TA. S.r.l.
Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
Assiut University
ADVANCED-3
Protara Therapeutics
RESCUE
Relmada Therapeutics, Inc.
The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.
Shenyang Sunshine Pharmaceutical Co., LTD.
TRAIN
The Christie NHS Foundation Trust
PERSEVERANCE
Institut Cancerologie de l'Ouest
Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer
ImmunityBio, Inc.
HERO
Fudan University
GEM-IR-NMIBC
Shanghai University of Traditional Chinese Medicine
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
Peking University First Hospital
BCG-TIME
Queen's University
Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy
Peking University First Hospital
T-Control® Safety for Cytostatics Management
Rethink Medical SL
BRACE
European Organisation for Research and Treatment of Cancer - EORTC
Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial
National Taiwan University Hospital
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Fujian Medical University Union Hospital
SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt
Fudan University
Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
POLO
University of Bern
RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer
West China Hospital
ProCSUCaB
Universitaire Ziekenhuizen KU Leuven